Article

Causative and susceptibility genes for Alzheimer's disease: a review.

Department of Neurosciences, Neurological Clinics, University of Pisa Medical School, Via Roma 67, 56126 Pisa, Italy.
Brain Research Bulletin (Impact Factor: 2.97). 07/2003; 61(1):1-24. DOI: 10.1016/S0361-9230(03)00067-4
Source: PubMed

ABSTRACT Alzheimer's disease (AD) is the most common type of dementia in the elderly population. Three genes have been identified as responsible for the rare early-onset familial form of the disease: the amyloid precursor protein (APP) gene, the presenilin 1 (PSEN1) gene and the presenilin 2 (PSEN2) gene. Mutations in these genes, however, account for less than 5% of the total number of AD cases. The remaining 95% of AD patients are mostly sporadic late-onset cases, with a complex aetiology due to interactions between environmental conditions and genetic features of the individual. In this paper, we review the most important genes supposed to be involved in the pathogenesis of AD, known as susceptibility genes, in an attempt to provide a comprehensive picture of what is known about the genetic mechanisms underlying the onset and progression of AD. Hypotheses about the role of each gene in the pathogenic pathway are discussed, taking into account the functions and molecular features, if known, of the coded protein. A major susceptibility gene, the apolipoprotein E (APOE) gene, found to be associated with sporadic late-onset AD cases and the only one, whose role in AD has been confirmed in numerous studies, will be included in a specific chapter. As the results reported by association studies are conflicting, we conclude that a better understanding of the complex aetiology that underlies AD may be achieved likely through a multidisciplinary approach that combines clinical and neurophysiological characterization of AD subtypes and in vivo functional brain imaging studies with molecular investigations of genetic components.

0 Bookmarks
 · 
100 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is the most common cause of dementia worldwide. As advancing age is the greatest risk factor for developing AD, the number of those afflicted is expected to increase markedly with the aging of the world's population. The inability to definitively diagnose AD until autopsy remains an impediment to establishing effective targeted treatments. Neuroimaging has enabled in vivo visualization of pathological changes in the brain associated with the disease, providing a greater understanding of its pathophysiological development and progression. However, neuroimaging biomarkers do not yet offer clear advantages over current clinical diagnostic criteria for them to be accepted into routine clinical use. Nonetheless, current insights from neuroimaging combined with the elucidation of biochemical and molecular processes in AD are informing the ongoing development of new imaging techniques and their application. Much of this research has been greatly assisted by the availability of transgenic mouse models of AD. In this review we summarize the main efforts of neuroimaging in AD in humans and in mouse models, with a specific focus on β-amyloid, and discuss the potential of new applications and novel approaches.
    Frontiers in Neuroscience 10/2014; 8:327.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUÇÃO A memória pode ser caracterizada como a aquisição, o armazenamento e a evocação de informações. Cada um destes processos é importante para a formação da memória, independente da classificação utilizada para avaliá-la. O princípio da investigação sobre os meca-nismos da memória data de mais de um século atrás, com Ebbinghaus (Izquierdo & Izquierdo 2004). Apesar da quantidade e complexidade dos processos que en-volvem sua formação, usamos praticamente as mesmas regiões do cérebro e mecanismos moleculares seme-lhantes para a construção de memórias distintas, exceto as áreas de linguagem (Izquierdo 2002). A aquisição é também denominada aprendizagem, que começa por volta dos 2 a 3 anos de idade. Os seres humanos não são capazes de fazer ou comunicar aqui-lo que desconhecem, e é através desta importante etapa que realizamos as tarefas mais comuns do dia-a-dia, como caminhar, comer ou falar. O armazenamento é a consolidação da memória. Nossa memória individual descarta o trivial, ao longo dos anos, perdemos fatos, lembranças ou conhecimentos que não nos interessam. E a evocação de informações retidas na memória é o que chamamos de recordação ou lembrança (Izquierdo 2002). O déficit de memória associado ao envelhecimento foi descrito pela primeira vez em 1986 pelo NIMH (Na-tional Institute of Mental Health), e não é considerada uma condição patológica (Crook et al. 1986). A sua de-finição seria uma diminuição subjetiva ou objetiva da memória, associada ao envelhecimento, e na ausência de déficit mais significativo da memória, que compro-meta a independência do indivíduo, de demência, ou de qualquer outra condição clínica ou psicopatológica que pudesse explicar os problemas de memória.
    Revista Brasileira de Biociências. 01/2011; 9:520-532.
  • Source
    Letters in Drug Design &amp Discovery 01/2013; · 0.96 Impact Factor